The costs of pivotal trials ranged from $2.1 million to $346.8 million, with a central cluster of trials with estimated costs of $12.2 million to $33.1 million.
Pivotal trials leading to FDA approval of novel therapies have a median cost of $19 million, with factors such as disease target and type of control cohort influencing costs, according to researchers.
The study of 138 pivotal trials assessing 59 new therapies that received FDA approval between 2015 and 2016 found more than 100-fold differences in the costs of clinical trials, along with the finding that a central cluster of trials has estimated costs of $12.2 million to $33.1 million.
“Pivotal clinical trial costs increased if more patients were needed to document treatment benefit, if active drug comparators were used, or to measure clinical end points rather than a change in surrogate outcome,” wrote the researchers.
To read about efforts to diversify clinical trials, click here.
They identified the novel therapeutic agents using the FDA Center for Drug Evaluation and Research annual summary reports on “Novel Drugs.” The characteristics of the trials were obtained through public sources, including ClinicalTrials.gov and the FDA Summary Review.
Of the 59 approved therapies, the most common disease target was cancer (30.5%), followed by endocrine and metabolic diseases (15.2%) and central nervous system disorders (13.6%). Just 16 agents were approved based on a standard review and 2 or more clinical trials, whereas 43 were granted 1 or more forms of expedited reviews or legal exceptions to the standard of 2 well-controlled trials.
The costs of trials ranged from $2.1 million for a trial that enrolled 4 patients to test uridine triacetate for a rare hereditary metabolic disorder to $346.8 million for a noninferiority trial that assessed the impact of a new combination cardiovascular drug for chronic heart failure on hospitalization and cardiovascular mortality. The clinical trials cost a median of $41,117 per patient and $3562 per patient visit.
The number of patients enrolled in the trial, as well as the type of control involved, also played a role in cost. Although median enrollment was 488 patients, trials had wide arrays of enrollment numbers, ranging from fewer than 15 patients for 3 trials for orphan drugs to more than 1000 patients in 21 other trials. Estimated costs increased from a mean of $5.9 million for trials with 100 or fewer patients to a mean of $77.2 million for the trials with more than 1000 patients.
Those without a control cohort had an estimated mean cost of $13.5 million, compared with placebo-controlled trials that had more than double the cost ($28.8 million) and active drug—controlled trials that had a mean cost of nearly $50 million ($48.9 million).
Other factors influencing costs included duration of treatment and type of end point. “An end point of clinical outcome more than doubled the mean trial cost compared with trials using either surrogate outcomes or clinical scales,” noted the researchers.
Reference
Moore T, Zhang H, Anderson G, Alexander GC. Estimated costs of pivotal trials for novel therapeutic agents approved the US Food and Drug Administration, 2015-2016 [published online September 24, 2018]. JAMA Intern Med. doi: 10.1001/jamainternmed.2018.3931.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More